Proceedings from the CIHLMU 5th Infectious Diseases Symposium 2016 “Drug Resistant Tuberculosis: Old Disease – New Challenge”

Authors: Celso Khosa, Krutarth Patel, Karlygash Abdiyeva, Nurkeldi Turebekov, Bettina Prüller & Norbert Heinrich

The 5th CIHLMU Infectious Disease Symposium, Munich, Germany, March 12, 2016 brought together Tuberculosis Experts from developed and low middle-income countries to discuss the control of drug resistance Tuberculosis. The meeting featured 9 presentations: Tuberculosis history and current scenario, Tuberculosis and migration - current scenario in Germany, Mechanism of Tuberculosis resistance development, Epidemiology of resistance – transmission vs. new generation of resistance, The impact of diagnostic in patients beyond – sensitivity and specificity, The Bangladesh regimen – new hope trough old drugs, New drugs and regimens – an overview on studies and Multi and Extensively Drug Resistant Tuberculosis from Europe. The presentations were followed by a panel discussion. Serious Multidrug Resistance epidemic in some countries may jeopardize the progress in Tuberculosis control. In this meeting epidemiology, mechanism, immigration and screening, diagnosis, research and treatment of drug resistant tuberculosis were discussed.

Published at:  2017-09-04

Limited value of whole blood Xpert® MTB/RIF for diagnosing tuberculosis in children

Authors: Christian Pohl a b c, Liliana K. Rutaihwa a b c, Frederick Haraka c, Martin Nsubuga d, Francesco Aloi d, Nyanda E. Ntinginya e, Daniel Mapamba e, Norbert Heinrich f g, Michael Hoelscher f g, Ben J. Marais h i, Levan Jugheli a b c, Klaus Reither a b c

We evaluated the ability of the Xpert® MTB/RIF assay to detect Mycobacterium tuberculosis in whole blood of children with tuberculosis in tuberculosis endemic settings with high rates of HIV infection. .......

Published at:  2016-10-15

CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo

Authors: Mkunde Chachage, Georgios Pollakis, Edmund Osei Kuffour, Kerstin Haase, Asli Bauer, Yuka Nadai, Lilli Podola, Petra Clowes, Matthias Schiemann, Lynette Henkel, Dieter Hoffmann, Sarah Joseph, Sabin Bhuju, Leonard Maboko, Fred Stephen Sarfo, Kirsten Eberhardt, Michael Hoelscher, Torsten Feldt, Elmar Saathoff, Christof Geldmacher

Interleukin 2 (IL-2) signaling through the IL-2 receptor alpha chain (CD25) facilitates HIV replication in vitro and facilitates homeostatic proliferation of CD25+ FoxP3+ CD4+ T cells. CD25+ FoxP3+ CD4+ T cells may therefore constitute a suitable subset for HIV infection and plasma virion production. CD25+ FoxP3+ CD4+ T cell frequencies, absolute numbers, and the expression of CCR5 and cell..........

Published at:  2016-09-29

Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study

Dr Inge Kroidl, MD Elmar Saathoff, PhD Lucas Maganga, MD Williams H Makunde, MD Prof Achim Hoerauf, MD Christof Geldmacher, PhD Petra Clowes, MD Leonard Maboko, PhD Prof Michael Hoelscher, MD

The past decades have seen an ongoing controversial debate about whether the immune activation induced by helminths has an effect on the susceptibility of individuals to HIV. In view of this, we assessed the effect of lymphatic filariasis, a chronic helminth disease elicited by Wuchereria bancrofti, on HIV incidence in southwest Tanzania.

Published at:  2016-08-02

Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort

Francesco Nicoli, Mkunde Chachage, Petra Clowes, Asli Bauer, Dickens Kowour, Barbara Ensoli, Aurelio Cafaro, Leonard Maboko, Michael Hoelscher, Riccardo Gavioli, Elmar Saathoff & Christof Geldmacher

The presence of IgG and IgM against Tat, an HIV protein important for viral replication and immune dysfunction, is associated with slow disease progression in clade B HIV-infected individuals. However, although Tat activities strictly depend on the viral clade, our knowledge about the importance of anti-Tat antibodies in non-clade B HIV infection is poor. The objective of this study was to investigate the association of different anti-Tat antibody isotypes with disease progression in non-clade B HIV-infected subjects and to study the relationship between anti-Tat humoral responses and immunological abnormalities.

Published at:  2016-07-22

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Cecilia Rademeyer,Bette Korber,Michael S. Seaman,Elena E. Giorgi,Ruwayhida Thebus,Alexander Robles,Daniel J. Sheward,Kshitij Wagh,Jetta Garrity,Brittany R. Carey,Hongmei Gao,Kelli M. Greene,Haili Tang,Gama P. Bandawe,Jinny C. Marais,Thabo E. Diphoko,Peter Hraber,Nancy Tumba,Penny L. Moore,Glenda E. Gray,James Kublin,M. Juliana McElrath,Marion Vermeulen,Keren Middelkoop,Linda-Gail Bekker,Michael Hoelscher,Leonard Maboko,Joseph Makhema,Merlin L. Robb,Salim Abdool Karim,Quarraisha Abdool Karim,Jerome H. Kim,Beatrice H. Hahn,Feng Gao,Ronald Swanstrom,Lynn Morris,David C. Montefiori,Carolyn Williamson

The development of biomedical interventions to reduce acquisition of HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high HIV-1 envelope diversity. Two large prophylactic trials in high incidence, clade C epidemic regions in southern Africa are imminent; passive administration of the monoclonal antibody VRC01, and active immunization with a clade C modified RV144-like vaccines. We have created a large representative panel of C clade viruses to enable assessment of antibody responses to vaccines and natural infection in Southern Africa, and we investigated the genotypic............

Published at:  2016-07-19

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

Agricola Joachim ,Asli Bauer ,Sarah Joseph,Christof Geldmacher,Patricia J. Munseri,Said Aboud,Marco Missanga,Philipp Mann,Britta Wahren,Guido Ferrari,Victoria R. Polonis,Merlin L. Robb,Jonathan Weber,Roger Tatoud,Leonard Maboko,Michael Hoelscher,Eligius F. Lyamuya,Gunnel Biberfeld,Eric Sandström,Arne Kroidl,Muhammad Bakari,Charlotta Nilsson,Sheena McCormack

A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously given three immunizations with HIV-DNA followed by two immunizations with recombinant modified vaccinia virus Ankara (HIV-MVA).

Published at:  2016-05-18

Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania

Inge Kroidl ,Elmar Saathof ,Lucas Maganga,Petra Clowes,Leonard Maboko,Achim Hoerauf,Williams H. Makunde,Antelmo Haule,Prisca Mviombo,Bettina Pitter,Neema Mgeni,Joseph Mabuye,Dickens Kowuor,Upendo Mwingira,Mwelecele N. Malecela,Thomas Löscher,Michael Hoelscher

Annual mass treatment with ivermectin and albendazole is used to treat lymphatic filariasis in many African countries, including Tanzania. In areas where both diseases occur, it is unclear whether HIV co-infection reduces treatment success.

Published at:  2016-04-12

Publication Archive

  • 2023 (6 publications)
  • 2022 (12 publications)
  • 2021 (5 publications)
  • 2020 (2 publications)
  • 2019 (2 publications)
  • 2018 (7 publications)
  • 2017 (8 publications)
  • 2016 (7 publications)
  • 2015 (7 publications)
  • 2014 (5 publications)
  • 2013 (5 publications)
  • 2012 (3 publications)
  • 2011 (4 publications)
  • 2010 (5 publications)
  • 2009 (5 publications)
  • 2008 (3 publications)
  • 2007 (3 publications)
  • 2006 (2 publications)
  • 2005 (2 publications)
  • 2004 (2 publications)
  • 2001 (1 publications)